BUZZ-Artelo Biosciences jumps as it plans UK study of glaucoma drug

Reuters

Mar 18

BUZZ-<a href="https://laohu8.com/S/ARTL">Artelo Biosciences</a> jumps as it plans UK study of glaucoma drug

** Shares of biotech firm Artelo Biosciences ARTL.O rise 55% to $7.35 premarket

** Co says it will test experimental cannabinoid drug, ART27.13, in glaucoma, an eye disease that damages vision by raising pressure inside the eye

** Says study in the UK will see if the oral capsule can safely lower eye pressure in people with glaucoma or ocular hypertension, a condition with higher‑than‑normal eye pressure

** Trial funded by Glaucoma UK and HSC R&D; patient enrolment to start in Q2 2026, co says

** Drug is designed to work outside the brain to avoid “high” or mind‑altering effects, co says

** ART27.13 is also being tested for cancer‑related weight loss; co says glaucoma study could expand its use - ARTL

** Shares down ~81% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2620995258"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620995258\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620995258?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 19:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620995258","market":"nz","top_or_hot":-1,"title":"BUZZ-Artelo Biosciences jumps as it plans UK study of glaucoma drug","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/ARTL\">Artelo Biosciences</a> jumps as it plans UK study of glaucoma drug</title></head><body><p>** Shares of biotech firm <a href=\"https://laohu8.com/S/ATLEW\">Artelo Biosciences</a> <span>ARTL.O</span> rise 55% to $7.35 premarket</p><p>** Co says it will test experimental cannabinoid drug, ART27.13, in glaucoma, an eye disease that damages vision by raising pressure inside the eye</p><p>** Says study in the UK will see if the oral capsule can safely lower eye pressure in people with glaucoma or ocular hypertension, a condition with higher‑than‑normal eye pressure</p><p>** Trial funded by Glaucoma UK and HSC R&amp;D; patient enrolment to start in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026, co says</p><p>** Drug is designed to work outside the brain to avoid “high” or mind‑altering effects, co says</p><p>** ART27.13 is also being tested for cancer‑related weight loss; co says glaucoma study could expand its use - ARTL</p><p>** Shares down ~81% in 2025</p><p>(Reporting by Sahil Pandey in Bengaluru)</p><p>((Sahil.Pandey@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Artelo Biosciences jumps as it plans UK study of glaucoma drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Artelo Biosciences jumps as it plans UK study of glaucoma drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-18 19:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/ARTL\">Artelo Biosciences</a> jumps as it plans UK study of glaucoma drug</title></head><body><p>** Shares of biotech firm <a href=\"https://laohu8.com/S/ATLEW\">Artelo Biosciences</a> <span>ARTL.O</span> rise 55% to $7.35 premarket</p><p>** Co says it will test experimental cannabinoid drug, ART27.13, in glaucoma, an eye disease that damages vision by raising pressure inside the eye</p><p>** Says study in the UK will see if the oral capsule can safely lower eye pressure in people with glaucoma or ocular hypertension, a condition with higher‑than‑normal eye pressure</p><p>** Trial funded by Glaucoma UK and HSC R&amp;D; patient enrolment to start in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026, co says</p><p>** Drug is designed to work outside the brain to avoid “high” or mind‑altering effects, co says</p><p>** ART27.13 is also being tested for cancer‑related weight loss; co says glaucoma study could expand its use - ARTL</p><p>** Shares down ~81% in 2025</p><p>(Reporting by Sahil Pandey in Bengaluru)</p><p>((Sahil.Pandey@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nL4N4060ZB:1","article_id":"2620995258","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620995258","pubTimestamp":1773834551,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Artelo Biosciences jumps as it plans UK study of glaucoma drug** Shares of biotech firm Artelo Biosciences ARTL.O rise 55% to $7.35 premarket** Co says it will test experimental cannabinoid drug, ART27.13, in glaucoma, an eye disease that damages vision by raising pressure inside the eye** Says study in the UK will see if the oral capsule can safely lower eye pressure in people with glaucoma or ocular hypertension, a condition with higherthannormal eye pressure** Trial funded by Glaucoma UK and HSC R&D; patient enrolment to start in Q2 2026, co says** Drug is designed to work outside the brain to avoid “high” or mindaltering effects, co says** ART27.13 is also being tested for cancerrelated weight loss; co says glaucoma study could expand its use - ARTL** Shares down ~81% in 2025","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","ARTL":"Artelo Biosciences, Inc."},"translate_title":"BUZZ-Artelo Biosciences计划在英国研究青光眼药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARTL":0.9},"content_text":"BUZZ-Artelo Biosciences jumps as it plans UK study of glaucoma drug** Shares of biotech firm Artelo Biosciences ARTL.O rise 55% to $7.35 premarket** Co says it will test experimental cannabinoid drug, ART27.13, in glaucoma, an eye disease that damages vision by raising pressure inside the eye** Says study in the UK will see if the oral capsule can safely lower eye pressure in people with glaucoma or ocular hypertension, a condition with higher‑than‑normal eye pressure** Trial funded by Glaucoma UK and HSC R&D; patient enrolment to start in Q2 2026, co says** Drug is designed to work outside the brain to avoid “high” or mind‑altering effects, co says** ART27.13 is also being tested for cancer‑related weight loss; co says glaucoma study could expand its use - ARTL** Shares down ~81% in 2025(Reporting by Sahil Pandey in Bengaluru)((Sahil.Pandey@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}